UPDATE – Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia

Sep 5, 2024

Ocuphire Pharma Announces Financial Results for Second Quarter 2024 and Provides Corporate Update

Aug 13, 2024

Ocuphire Pharma to Present at Two Investor Conferences in August

Aug 8, 2024

Ocuphire Pharma to Highlight APX3330 for Diabetic Retinopathy at Two Scientific Meetings in July

Jul 10, 2024

Ocuphire Pharma Announces Presentations on the Development of APX3330 for Diabetic Retinopathy at Retina Meetings in June

Jun 6, 2024

Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update

May 10, 2024

Ocuphire Pharma Announces Presentation on APX3330 at the ARVO 2024 Annual Meeting

May 6, 2024

Ocuphire Pharma to Present at the Aegis Virtual Conference

May 3, 2024

First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery

Apr 11, 2024

Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris

Apr 1, 2024